Volume 12, Issue 3 (Autumn 2015)                   bloodj 2015, 12(3): 223-232 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Fallah P, Timori Naghadeh H, Soleimani M, Amirizadeh N, Poopak B, Toogeh G, et al . The assessment of miR-150 and miR-155 on chronic myelogenous leukemia patients. bloodj 2015; 12 (3) :223-232
URL: http://bloodjournal.ir/article-1-906-en.html
The assessment of miR-150 and miR-155 on chronic myelogenous leukemia patients
P. Fallah , H. Timori Naghadeh * , M. Soleimani , N. Amirizadeh , B. Poopak , Gh. Toogeh , E. Arefian , Sh. Bolouri , T. Golkar , Z. Pirmohammad Jamaat
Keywords: Key words : MicroRNAs, miR-150 ٬ human, miR-155 ٬ human, Leukemia ٬ Chronic Myelogenous
Full-Text [PDF 383 kb]   (5813 Downloads)     |   Abstract (HTML)  (8901 Views)
Full-Text:   (2797 Views)
References :  
  1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344(14): 1038-42.
  2. Xiong Q, Yang Y, Wang H, Li J, Wang S, Li Y, et al. Characterization of miRNomes in acute and chronic myeloid leukemia cell lines. Genomics Proteomics Bioinformatics 2014; 12(2): 79-91.
  3. Dzikiewicz-Krawczyk A, Macieja A, Maly E, Januszkiewicz-Lewandowska D, Mosor M, Fichna M, et al. Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding. J Hematol Oncol 2014; 7(1): 43.
  4. Vaz C, Ahmad HM, Bharti R, Pandey P, Kumar L, Kulshreshtha R, et al. Analysis of the microRNA transcriptome and expression of different isomiRs in human peripheral blood mononuclear cells. BMC Res Notes 2013; 6: 390.
  5. Venturini  L,   Battmer   K,   Castoldi  M, Schultheis B, Hochhaus A, Muckenthaler MU, et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 2007; 109(10): 4399-405.
  6. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435(7043): 834-8.
  7. Harquail J, Benzina S, Robichaud GA. MicroRNAs and breast cancer malignancy: an overview of miRNA-
 
 
 
 
regulated cancer processes leading to metastasis. Cancer Biomark 2012; 11(6): 269-80.
  1. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010; 42(8): 1273-81.
  2. Lazare SS, Wojtowicz EE, Bystrykh LV, de Haan G. microRNAs in hematopoiesis. Exp Cell Res 2014; 329(2): 234-8.
  3. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 2008; 22(6): 1095-105.
  4. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111(10): 5078-85.
  5. Tricoli JV, Jacobson JW. MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis. Cancer Res 2007; 67(10): 4553-5.
  6. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33(20): e179.
  7. Merkerova M, Belickova M, Bruchova H. Differential expression of microRNAs in hematopoietic cell lineages. Eur J Haematol 2008; 81(4): 304-10.
  8. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J. The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 2010; 84(1): 1-16.
  9. Zhao H, Wang D, Du W, Gu D, Yang R. MicroRNA and leukemia: tiny molecule, great function. Crit Rev Oncol Hematol 2010; 74(3): 149-55.
  10. Garzon  R,  Croce  CM.   MicroRNAs  in   normal   and
malignant hematopoiesis. Curr Opin Hematol 2008; 15(4): 352-8.
  1. Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology 1999; 13(2): 169-80; discussion 181, 184.
  2. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108(1): 28-37.
  3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75(5): 843-54.
  4. Cheng J, Guo S, Chen S, Mastriano SJ, Liu C, D'Alessio AC, et al. An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis. Cell Rep 2013; 5(2): 471-81.
 
  1. Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109(11): 4944-51.
  2. Santhi WS, Prathibha R, Charles S, Anurup KG, Reshmi G, Ramachandran S, et al. Oncogenic microRNAs as biomarkers of oral tumorigenesis and minimal residual disease. Oral Oncol 2013; 49(6): 567-75.
  3. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17(1): 28-40.
  4. Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 2010; 95(8): 1325-33.
  5. Machova Polakova K, Lopotova T, Klamova H, Burda P, Trneny M, Stopka T, et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer 2011; 10: 41.
  6. Rokah OH, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One 2012; 7(4): e35501.
 
 
 
 
 
 
 


 
 
 
 
 
Sci J Iran Blood Transfus Organ 2015; 12(3): 223-232
 
Original  Article
 
 

The assessment of miR-150 and miR-155 on chronic
myelogenous leukemia patients
 
Fallah P.1,2, Timori Naghadeh H.1, Soleimani M.3, Amirizadeh N.1, Poopak B.4, Toogeh Gh.5,
Arefian E.6, Bolouri Sh.7, Golkar T.7, Pirmohammad Jamaat Z.1
 
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
2Allied-Health Faculty, Alborz University of Medical Sciences, Karaj, Iran
3Department of Hematology and Blood Banking, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
4School of Allied Medicine, Medical Branch of Islamic Azad University, Tehran, Iran 
5School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
6Biology School of Tehran University, Tehran, Iran
7Payvandlab Clinical & Speciality Laboratory, Tehran, Iran
 
Abstract
Background and Objectives
Micro RNAs are a class of small non-coding RNAs which have been recently shown to play a crucial role in major cellular processes such as development and differentiation through post-transcriptional regulation. The correlation of microRNA expression levels with the pathogenesis of some hematologic malignancies including acute myeloid leukemia is already known. The aim of this study was to investigate the expression of mir-150 and mir-155 in chronic myelogenous leukemia patients. miRNA expression level changes can be used for diagnosis, treatment and estimation of Minimal Residual Disease (MRD).
 
Materials and Methods
In this descriptive study, the expression of miR-150 and miR-155 in 25 newly diagnosed CML patients in chronic phase and 25 healthy subjects as the control all in Payvand Medical Laboratory were examined by Stem-loop RT-PCR and Real Time PCR techniques. For data analysis, Pearson correlation analysis was used.
 
Results
miR-150 and miR-155 were down-regulated in CML patients rather than in healthy subjects (0.512 and 0.2552, respectively). There was no correlation between the laboratory findings and the miR expression level. But miR-155 was inversely associated with age (p ≤  0.01).
 
Conclusions
In conclusion, the decreasing expression of miR-150 and miR-155 in chronic myelogenous leukemia is indicative of their induced expression in suppressing proliferation of cells in this disease. Other studies are also required to elucidate the exact role of microRNA by identifying their target genes.
 
Key words: MicroRNAs, miR-150٬ human, miR-155٬ human, Leukemia٬ Chronic Myelogenous
 
Received: 15  Oct 2014
Accepted: 23 Jan 2015
 
 
 

Correspondence: Timori Naghadeh H., Pathologist. Assistant Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 1157-14665, Tehran, Iran. Tel: (+9821) 88601564; Fax: (+9821) 88060717
E-mail: timori13@gmail.com
Correspondence: Soleimani M., PhD of Hematology. Associate Professor of Department of Hematology and Blood Banking, Faculty of Medical Sciences, Tarbiat Modares University.
P.O.Box: 14115-111, Tehran, Iran. Tel: (+9821) 88011001; Fax: (+9821) 88013030
E-mail: soleim_m@modares.ac.ir
Type of Study: Research | Subject: Hematology
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Iranian Blood Transfusion

Designed & Developed by: Yektaweb